Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Longdaysin
Cat. No.:
0225LY-1286
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Longdaysin inhibits CK1α and CK1δ with IC50 values of 5.6 μM and 8.8 μM, respectively, and can also target ERK2.
Synonym:
1353867-91-0; 9-isopropyl-N-(3-(trifluoromethyl)benzyl)-9H-purin-6-amine; 9-propan-2-yl-N-[[3-(trifluoromethyl)phenyl]methyl]purin-6-amine
CAS No.:
1353867-91-0
Compound CID:
49830252
Formula:
C16H16F3N5
Formula Weight:
335.33
Specification
Targets&IC50:
CDK7: 29 μM (cell free); ERK2: 52 μM (cell free); CKIα: 5.6 μM (cell free); CKIδ: 8.8 μM (cell free)
Relative Density:
1.35 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Longdaysin can be used in circadian rhythm research to investigate the modulation of the biological clock through the inhibition of multiple kinases.
Library Information
Target:
CDK; ERK; Casein kinase
Receptor:
CDK; CDK7; CKIα; CKIδ; ERK2
Pathways:
Stem cell regulation; MAPK; Cell cycle/Checkpoint; Metabolism
Plate Number:
AOCL-17
Plate Location:
e3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
100 mg/mL; 298.21 mM
